Cipla is set to launch coronavirus COVID-19 treatment drug favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process.

An off-patent anti-viral drug, favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild and moderate cases.

CSIR-Indian Institute of Chemical Technology (CSIR-IICT) developed a cost effective process using locally available chemicals to synthesise this active pharmaceutical ingredient (API) and transferred the technology to Cipla.

"Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India," the statement said.

Commenting on the development, director CSIR-IICR, Dr S Chandrashekhar said that the technology provided by CSIR-IICT is very efficient and makes it affordable and allows Cipla to make large quantities of the product within a short span of time.

DG-CSIR, Dr Shekhar C Mande observed that CSIR is working with industry in developing quick solutions and products for mitigation of COVID-19 and this partnership with Cipla is an example of how CSIR is committed in bringing repurposed drugs on a fast track.